Dear Sir, Latent autoimmune diabetes in adults (LADA) is considered to be a form of autoimmune diabetes that resembles type 1 diabetes though, with a later onset and slower progression toward absolute insulin requirement. There is no therapeutic strategy for LADA [1] . Here we report a patient with LADA, who showed increased intrinsic insulin secretion by the addition of metformin, and sitagliptin or exenatide to the insulin therapy.
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A 68-year-old woman, diagnosed to have diabetes in late 40s was treated with oral hypoglycemic agents for 17 years before insulin therapy in 2009. HbA1c levels were 6-7 % until March in 2012. Plasma glucose (520 mg/dL) and HbA1c (11.5 %) levels were high. She has been treated by using 10, 8 and 8 units of insulin glulisine before breakfast, lunch and dinner, respectively, and 18 units of insulin glargine before breakfast. Her body weight was 66.0 kg and height 152.0 cm (BMI 28.6 kg/m 2 ). The titer of anti-GAD antibody was elevated (34.0 U/ml; normal, <1.5 U/ml), and her urinary C-peptide level was reduced (4.6 μg/day; normal, 29.2-167 μg/day), suggesting LADA. Because an increase of insulin dose stimulated her appetite strongly, we started her on metformin in July, 2012, which improved her blood glucose and also increased her urinary C-peptide (22.3 μg/day) in November, 2012. The addition of sitagliptin (50 mg/day) induced more insulin secretion (52.9 μg/day), however, could not suppress her appetite completely. Therefore, we switched from sitagliptin to exenatide (10 μg/day), which remarkably suppressed her appetite and also significantly reduced daily insulin requirement (from 42 units/day to 16 units/day), and maintained intrinsic insulin secretion (51.2 μg/day).
There are no studies that evaluated metformin in patients with LADA, possibly due to potential risk for the development of lactic acidosis by metformin in patients who progress toward insulin dependency [2] . We used metformin with insulin, which improved blood glucose and increased intrinsic insulin secretion without the development of lactic acidosis. To our knowledge, our report is the first to show that the addition of GLP-1 receptor agonist and dipeptidyl-peptidase-4 (DPP-4) inhibitor to insulin increased intrinsic insulin secretion in a patient with LADA.
In summary, the addition of metformin and GLP-1 receptor agonist or DPP-4 inhibitor to insulin may be a promising therapeutic option for LADA.
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